Senesco Technologies, Inc. To Webcast, Live, At RetailInvestorConferences.com On December 1st
NEW YORK, Nov. 29, 2011 /PRNewswire/ -- Senesco Technologies, Inc. (NYSE AMEX: SNT) announced that that Leslie J. Browne, Ph.D., President and CEO, will present at RetailInvestorConferences.com.
DATE: December 1, 2011TIME: 10:00 AM ESTLINK: www.retailinvestorconferences.com > Click the red "register/ watch event now" button.
This will be a live, interactive online event where investors are invited to ask the company questions in real-time both in the presentation hall as well as the company's "virtual trade booth." If attendees are not able to join the event live in real-time, an on-demand archive will be available for 90 days.
It is recommended that investors pre-register to save time and receive event updates.Senesco recently initiated patient dosing at the Mayo Clinic in Rochester, MN, in a Phase 1b/2a clinical study of SNS01-T, the Company's lead therapeutic candidate for the treatment of multiple myeloma, and also indicated its plan to initiate in 2012 an additional clinical study of SNS01-T in other B-cell cancers. The Company has demonstrated in the laboratory that SNS01-T can significantly inhibit the growth of both human mantle cell and diffuse large B-cell lymphomas in a dose dependent manner in mouse xenograft models. Potential additional effectiveness was observed from in vitro studies in which SNS01-T was combined with other approved myeloma drugs. "We believe we have shown that certain myeloma drugs can be up to 40 times more potent in vitro when used in combination with SNS01-T," stated Leslie J. Browne, Ph.D., President and CEO of Senesco. "Together these results further reinforce the significance of our target, eIF5A, and will guide us in designing our future clinical studies." About Multiple Myeloma Multiple myeloma is an incurable cancer of plasma cells, a type of white blood cell derived from B-lymphocytes, normally responsible for the production of antibodies. Malignant plasma cells accumulate in the bone marrow leading to bone lesions and interfering with the production of normal white blood cells. Median survival time from first treatment is 2½ to 5 years depending on disease stage at diagnosis. In the United States there are approximately 20,000 newly diagnosed cases of multiple myeloma annually and a total of approximately 65,000 patients with the disease. Senesco was previously granted orphan drug status for SNS01-T, the Company's lead drug candidate for treatment of multiple myeloma. About Senesco Technologies, Inc. Senesco Technologies is leveraging proprietary technology that regulates programmed cell death, or apoptosis. Accelerating apoptosis may have applications in treating cancer, while delaying apoptosis may have applications treating certain inflammatory and ischemic diseases. The Company has initiated a clinical study in multiple myeloma with its lead therapeutic candidate SNS01-T. Senesco has already partnered with leading-edge companies engaged in agricultural biotechnology, and is entitled to earn research and development milestones and royalties if its gene-regulating platform technology is incorporated into its partners' products.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV